PREVALENCE OF FIBROMYALGIA IN RUSSIA
Lev L1, Nasonov E2, Soldatov D1, Taev C1
1Pierre Fabre, Boulogne, France, 2Rheumatology Institute, Moscow, Russia, Pierre Fabre Laboratories, Moscow, Russia

OBJECTIVES: To assess the estimated prevalence of fibromyalgia syndrome (FM) among the adult population in the general population in Russia, using the London Fibromyalgia Epidemiology Study - Screening Questionnaire (LFESSQ) and American College of Rheumatology (ACR) classification criteria. METHODS: The validated Russian version of the LFESSQ was administered to a representative community sample of 1,610 subjects aged over 15 years, selected by the quota method. A positive screen was defined as: (1) meeting the 4-pain criteria alone (LFESSQ≥4), or meeting both the 4-pain and the 18-point FM criteria (LFESSQ≥6). The questionnaire on rheumatology outpatients (n = 399), who were then examined by a trained rheumatologist to confirm or exclude the diagnosis of FM according to the 1990 American College of Rheumatology criteria. The prevalence of FM in the general population was estimated by applying the predictive positive value to eligible community subjects (i.e., positive screens). RESULTS: In the community sample, 13.8% screened positive for LFESSQ≥6 (18.4% in females and 8.1% in males respectively). Among rheumatology outpatients, 43.6% were screened positive (44.3% in females and 40.5% in males respectively), whereas 5.4% were confirmed FM cases. The prevalence of FM was estimated at 2.1% (95% CI 1.4%-2.8%), 2.8% in females and 1.2% in males respectively) in the Russian general population. CONCLUSIONS: Our findings are in agreement with those of earlier national survey reports. A point prevalence of 2.1% would translate in approximately 2.5 million of patients with FM in Russia.

THE RELATIONSHIP BETWEEN SURGICAL DELAY OVER 24 HOURS AND 30 DAYS MORTALITY FOLLOWING FEMORAL NECK FRACTURE IN THE PRESENCE OF DIFFERENT CO-MORBIDITIES
Sebestyén A1, Bonce M2, Molnár A1, Kőrösi L1, Kirschbauer I1, Brodsky V2, Golács L1, Sándor P1
1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3National Health Insurance Fund Administration (OIEP), Budapest, Hungary, 4University of Pécs, Pécs, Hungary, 5Karviná University of Budapest, Budapest, Hungary

OBJECTIVES: The aim of our study is to analyze the relationship between surgical delay over 24 hours and 30 days mortality following femoral neck fracture in the presence of different co-morbidities in patients aged over 60 years. METHODS: Data were derived from the database of the National Health Insurance Fund Administration according to the ICD 10th revision’s S720 code. The study included patients aged over 60 years, who were discharged from inpatient care institutions following the treatment of femoral neck fractures. The patients with polytrauma were excluded from the study. In case of surgical delay six months mortality was the reference. Data were evaluated according to sex, age, type of fracture, patient turnover of institutions, type of surgery, early complications, hospital type, day of operation. The following co-morbidities were included into the analysis: C00-C07, D60-D64, E10-E16, F00-F99, G20-G26, G80-G83, I10-I15, I20-I25, I30-I32, I60-I69, I70, J00-J22, J40-J47, L89, N30-N39. Statistical analysis has been performed by logistic regression (Odds Ratio[95%CI], p < 0.05). RESULTS: Altogether 3783 patients were involved into the study. Surgical delay (24 h±0-6 h) OR = 1.3099, p = 0.0095. The following co-morbidities (ICD codes with OR and p value) proved to be statistically significant predictors: I10-I15: 2.0759(0.0136), I60-I69: 2.5104(0.0498), J40-J47: 2.8177(0.0305). CONCLUSIONS: Mortality in elderly femoral neck fracture treated with hip endoprosthetics is higher in patients with DMG than in patients without. Mortality in patients with polytrauma is increased also in patients with co-morbidities.

RELATIONSHIP BETWEEN SURGICAL INTERVENTION TYPE AND 30 DAYS MORTALITY OF ELDERLY FEMORAL NECK FRACTURE IN THE PRESENCE OF DIFFERENT CO-MORBIDITIES
Sebestyén A1, Bonce M2, Molnár A1, Kőrösi L1, Kirschbauer I1, Oláh A1, Pentek P1, Sándor P1
1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3National Health Insurance Fund Administration (OIEP), Budapest, Hungary, 4University of Pécs, Pécs, Hungary, 5For Ferencz County Hospital, Kistács, Hungary

OBJECTIVES: The aim of our retrospective study is to analyze the relationship between surgical intervention type and 30 days mortality following femoral neck fracture in the presence of different co-morbidities in patients aged over 60 years. METHODS: Data were derived from the database of the National Health Insurance Fund Administration according to the ICD 10th revision’s S720 code. The study included patients aged over 60 years old discharged from inpatient care institutions following the primary treatment of femoral neck fractures. The patients with polytrauma were excluded from the study. Osteosynthesis was compared to arthroplasty as reference surgical method. Data were evaluated according to sex, age, type of fracture, patient turnover of institutions, surgical delay, early complications, hospital type, day of operation. The following co-morbidities were included into the analysis: C00-C07, D60-D64, E10-E16, F00-F99, G20-G26, G80-G83, I10-I15, I20-I25, I30-I32, I60-I69, I70, J00-J22, J40-J47, L89, N30-N39. Statistical analysis has been performed by logistic regression (Odds Ratio[95%CI], p < 0.05). RESULTS: Altogether 3783 patients were involved into the study. Type of surgical intervention (osteoarthroplasty vs. arthroplasty) OR: 1.7265, p = 0.0128. The following co-morbidities (ICD codes with OR and p value) proved to be statistically significant predictors: I10-I15: 2.0759(0.0136), I60-I69: 2.5104(0.0498), J40-J47: 2.8177(0.0305). CONCLUSIONS: Mortality in elderly femoral neck fracture treated with hip endoprosthetics is higher in patients with DMG than in patients without. Mortality in patients with polytrauma is increased also in patients with co-morbidities.

ESTIMATION OF COSTS RELATED TO ADVERSE EVENTS IN NSAID TREATMENT OF OSTEOARTHRITIS – A COMPARISON BETWEEN CELECOXIB AND IBUPROFEN USING A VALIDATED MODEL
Rasch DW1, Campbell HM2, Khan N3, Site J3
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, 3University of New Mexico, Albuquerque, NM, USA

OBJECTIVES: To measure the health care utilization of US veteran patients with gout and to determine additional costs associated with difficult to manage gout (DMG). METHODS: Using diagnostic codes (ICD-9 CD – 274.XX), we identified patients from the National Veterans Affairs Health System (VA) databases. We then collected all administrative data (demographic, inpatient and outpatient care, pharmacy, laboratory, and tests) for these patients over the years 2004–2006. DMG patients were identified by diagnostic codes associated with complications of the skin (tophi), eye, nerve, and kidney. We created data summaries for each patient by year; including diagnoses, treatments, drug therapies, laboratory tests, and surgeries. RESULTS: There were 290,772 patients identified in 2004. Each year, healthcare costs per patient were significantly higher (Kruskal Wallis tests, P < 0.001) for DMG versus other gout patients: inpatient costs in 2006. In addition DMG patients were significantly (P < 0.001), had higher Charlson co-morbidity scores and were more likely to have concomitant cardiovascular, renal, and liver diseases. A limitation of the study is the lack of specificity of diagnostic codes for complications due to gout, which may impact the sample size. CONCLUSIONS: Health care costs are significantly higher for DMG patients. We note that increased inpatient plus outpatient costs for DMG patients were $10,000 to $16,000 per patient-year. These VA patients also have significantly more co-morbid conditions than other gout patients.